Vasculitis, ANCA-Associated

Comprehensive Clinical Guide: ANCA-Associated Vasculitis (AAV)

ANCA-associated vasculitis (AAV) represents a group of systemic, autoimmune, necrotizing small-vessel vasculitides characterized by the presence of circulating anti-neutrophil cytoplasmic antibodies (ANCAs). These conditions are life-threatening, multi-systemic disorders that require rapid diagnostic intervention and aggressive immunosuppressive therapy.

1. Clinical Definition and Classification

AAV is defined by the inflammation of small vessels (capillaries, venules, and arterioles) with little to no immune complex deposition, a phenomenon historically termed "pauci-immune" vasculitis. The Chapel Hill Consensus Conference (CHCC) classifies AAV into three primary clinical phenotypes:

• Granulomatosis with Polyangiitis (GPA): Formerly Wegener’s granulomatosis; characterized by necrotizing granulomatous inflammation, typically involving the upper and lower respiratory tracts, often with renal involvement.
• Microscopic Polyangiitis (MPA): A systemic, necrotizing vasculitis with few or no immune deposits, typically affecting the kidneys and lungs, but lacking the granulomatous features of GPA.
• Eosinophilic Granulomatosis with Polyangiitis (EGPA): Formerly Churg-Strauss syndrome; characterized by eosinophil-rich, granulomatous inflammation involving the respiratory tract, often with asthma and peripheral blood eosinophilia.

2. Pathophysiology and Etiology

The pathogenesis of AAV is a complex interplay between genetic predisposition, environmental triggers, and dysregulated immune responses.

The Role of ANCAs

The hallmark of AAV is the production of autoantibodies against neutrophil enzymes, primarily:
1. Proteinase 3 (PR3-ANCA): Highly associated with GPA.
2. Myeloperoxidase (MPO-ANCA): Highly associated with MPA and EGPA.

Mechanistic Pathway

1. Priming: Neutrophils are "primed" by pro-inflammatory cytokines (e.g., TNF-α), causing the translocation of PR3 and MPO to the cell surface.
2. Activation: ANCA antibodies bind to these surface antigens, triggering neutrophil degranulation and the release of reactive oxygen species (ROS) and lytic enzymes.
3. Alternative Complement Pathway: Activation of the C5a receptor creates a positive feedback loop, further recruiting neutrophils and amplifying vascular damage.
4. Endothelial Injury: The resulting neutrophil extracellular traps (NETs) and endothelial damage lead to vessel wall necrosis, fibrinoid change, and organ ischemia.

3. Clinical Presentation and Staging

Standard Presentation

The clinical presentation is highly variable, ranging from localized upper airway involvement to fulminant multi-organ failure.

Staging (Birmingham Vasculitis Activity Score - BVAS)

The BVAS is the gold-standard tool for clinical assessment. It categorizes disease activity into "Persistent," "Remission," or "Relapse."
* Localized: Limited to upper/lower respiratory tract.
* Early Systemic: Systemic symptoms without organ-threatening disease.
* Generalized: Renal or other organ-threatening disease.
* Severe: Organ failure (e.g., dialysis-dependent renal failure, pulmonary hemorrhage).

4. Diagnostic Workup

A definitive diagnosis requires a combination of serology, imaging, and histopathology.

Key Diagnostic Tests

1. Serology (Indirect Immunofluorescence & ELISA): The primary screening tool. ANCA positivity alone is insufficient for diagnosis; it must be correlated with clinical findings.
2. Renal Biopsy: The gold standard. Look for "pauci-immune" necrotizing crescentic glomerulonephritis.
3. Imaging:
   • High-Resolution CT (HRCT): Essential for identifying pulmonary nodules, infiltrates, or fibrosis.
   • MRI/MRA: Used for large vessel involvement or CNS vasculitis.
4. Urinalysis: Monitoring for red cell casts and proteinuria as markers of active renal disease.

5. Differential Diagnosis

Distinguishing AAV from other systemic inflammatory diseases is critical due to differences in treatment protocols.

• Goodpasture’s Syndrome (Anti-GBM disease): Differentiated by linear IgG deposits on basement membrane biopsy.
• Systemic Lupus Erythematosus (SLE): Presence of ANA and anti-dsDNA; immune complex deposition (not pauci-immune).
• Infective Endocarditis: Can mimic systemic vasculitis; ruled out via blood cultures and echocardiography.
• Malignancy: Pulmonary nodules and hematuria can mimic AAV; requires biopsy to rule out lymphoma or lung cancer.

6. Treatment Strategy and Management

Management is divided into Induction of Remission and Maintenance Therapy.

Induction Therapy

• First-line: Rituximab or Cyclophosphamide combined with high-dose glucocorticoids.
• Adjunctive: Plasma exchange (PLEX) for patients with severe pulmonary hemorrhage or rapidly declining creatinine (based on the PEXIVAS trial results).

Maintenance Therapy

• Rituximab: Now considered superior to Azathioprine for long-term maintenance in preventing relapses.
• Azathioprine or Methotrexate: Standard alternatives for maintenance.

7. Risks, Side Effects, and Contraindications

The aggressive nature of induction therapy carries significant clinical risks:

• Infection: The primary cause of mortality in AAV patients. Prophylaxis for Pneumocystis jirovecii pneumonia (PJP) is mandatory for patients on high-dose immunosuppression.
• Cyclophosphamide Toxicity: Hemorrhagic cystitis, bladder cancer, and infertility.
• Glucocorticoid Side Effects: Osteoporosis, avascular necrosis, hyperglycemia, and hypertension.
• Rituximab Infusion Reactions: Hypersensitivity, Cytokine Release Syndrome (CRS).

8. Long-Term Prognosis

The prognosis of AAV has improved significantly over the last three decades, moving from a fatal disease to a chronic, manageable condition. However, it remains a serious systemic illness.

• Mortality: Highest in the first year due to active disease and infection.
• Morbidity: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are common long-term sequelae.
• Relapse: AAV is characterized by a high relapse rate (up to 50% within 5 years), necessitating lifelong surveillance.

9. Frequently Asked Questions (FAQ)

1. Is AAV a genetic disease?

While there are genetic associations (e.g., HLA-DPB1), AAV is not strictly hereditary. It is considered a multifactorial autoimmune condition triggered by environmental factors.

2. What is the difference between GPA and MPA?

GPA typically involves granulomatous inflammation and upper airway involvement, whereas MPA is usually limited to small vessels without granulomas.

3. Can I be ANCA-negative and still have AAV?

Yes. Approximately 10-20% of patients with clinical features of AAV may be ANCA-negative (ANCA-negative AAV), requiring biopsy for confirmation.

4. How often do I need blood tests?

During induction, monthly or bi-monthly. During maintenance, every 3-6 months, depending on clinical stability and medication regimen.

5. Why is Rituximab preferred over Cyclophosphamide?

Rituximab has shown non-inferiority in induction and superior efficacy in maintenance, with a more favorable side-effect profile regarding fertility.

6. Does AAV cause permanent lung damage?

Yes, pulmonary scarring, fibrosis, and chronic airway obstruction can persist even after the disease is in remission.

7. Is pregnancy safe with AAV?

Pregnancy is high-risk in AAV patients. It should be planned during stable remission, as some medications (cyclophosphamide) are teratogenic, and the disease can flare during gestation.

8. What is the role of the "Pauci-immune" classification?

It confirms that the vessel damage is not caused by the deposition of immune complexes, which helps distinguish AAV from diseases like Lupus nephritis.

9. What are the warning signs of a relapse?

New or worsening sinusitis, hematuria, hemoptysis, or sudden onset of neuropathy (e.g., wrist drop).

10. Is there a cure for AAV?

There is no "cure" in the sense of complete elimination of the disease, but there is "sustained remission," which allows patients to lead normal lives with periodic monitoring.

10. Specialist Clinical Summary Table

Disclaimer: This guide is intended for educational and professional medical reference purposes only. Clinical decisions should be based on individual patient assessment, current institutional protocols, and multidisciplinary specialist consultation.